Capturing a Visionary: Dr. Gilberto Lopes Joins Immorta Bio’s Advisory Board

As a fellow member of Immorta Bio’s Strategic Advisory Board, Bob Gordon was honored to direct and produce the official announcement introducing world-renowned oncologist Dr. Gilberto Lopes.

A global leader in lung cancer and immuno-oncology, Dr. Lopes is best known for his role as principal investigator of KEYNOTE-042, the clinical trial that led to the FDA approval of Keytruda® for advanced non–small cell lung cancer—expanding access to life-saving immunotherapy worldwide.

Now, as he steps into his advisory role at Immorta Bio, Dr. Lopes supports the company’s mission to extend human healthspan through next-generation therapies like SenoVax™—a first-in-class senolytic immunotherapy that trains the immune system to eliminate aging, dysfunctional cells.

Through Bob’s lens, this announcement captured not just Dr. Lopes’ scientific legacy, but his humanity. A physician whose research continues to shape the future of oncology—and now, the future of longevity.

Watch the full interview on Yahoo Finance News.

Visit Immorta Bio website for more info.